首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

2126368

動態物標記市場－策略分析與預測（2026-2035）

Pharmacodynamic Biomarkers Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月06日 | 出版商:

Knowledge Sourcing Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計動態物標記市場將從 2026 年的 56.3 億美元成長到 2035 年的 146.3 億美元，複合年成長率為 11.2%。

受精準醫療模式轉移和藥物研發日益複雜化的驅動，動態物標記市場正經歷顯著的變化。這一市場演變的特點是，人們越來越認知到客觀的生物學指標對於證明療效、最佳化劑量和支持監管決策至關重要。免疫檢測、次世代定序和質譜等先進分析平台的融合，使得對治療性介入的生物學反應進行更準確、更全面的測量成為可能。製藥公司正在臨床開發的各個階段應用動態物標記物，因為早期生物學證據能夠提高決策效率並降低研發風險。監管機構也日益認知到生物標記是支持藥物研發和精準醫療計劃的重要工具。隨著對多組體學技術、人工智慧驅動的生物標記發現和轉化研究基礎設施的大量投資，動態學生物標記正在成為全球醫療保健和製藥生態系統中現代藥物研發的關鍵組成部分。

市場促進因素

精準醫療計畫的擴展是動態物標記市場的主要驅動力。精準醫療依賴能夠指導個人化治療策略的生物資訊。隨著治療效果越來越依賴對患者層面生物反應的理解，對動態物標記的需求也不斷成長。這項需求要求研發人員提供客觀證據來支持治療方案的最佳化。製藥公司正在擴展其生物標記項目，以改善患者選擇和治療結果。因此，生物標記在臨床開發和個人化醫療中的整合正在不斷推進，動態學生物標記的應用也持續擴大。標靶治療的日益普及進一步加速了市場成長，因為其需要對生物活性進行客觀評估。標靶治療需要確認治療性介入能夠影響預期的生物路徑。隨著研發人員尋求評估標靶結合和生物活性的客觀方法，對動態物標記的需求也不斷成長。這種依賴性限制了僅依靠傳統療效評估方法的限制。產業相關人員正在加強生物標記開發力度，以改善治療評估並減少研發過程中的不確定性。因此，基於生物標記的治療開發策略正被更廣泛地採用。臨床試驗中生物標記的日益普及加速了其在整體治療開發過程中的整合。臨床試驗越來越需要能夠支持治療評估和患者分層的生物學證據。隨著申辦方尋求更有效率的治療效果評估方法，對動態物標誌物的需求也不斷成長。這項挑戰促使研究人員開發能夠準確反映生物反應的生物標記。各機構正在將生物標記納入試驗設計，以改善決策和資源分配。多組體學技術的進步正在加速整個動態物標誌物開發專案的創新。現代生物標記的發現取決於能夠評估複雜生物系統的技術。治療開發中對分子反應進行全面表徵的需求日益成長，推動了對精密分析平台的需求。

市場限制因素

由於不同患者群體和疾病狀態下的生物學反應存在差異，生物標記的檢驗仍然十分複雜。治療反應的生物學變異性使得對生物標記進行一致的解讀變得困難。由於不同實驗室和臨床開發項目的調查方法和檢測平台各不相同，標準化挑戰依然存在。缺乏統一的方案降低了可比性和臨床可靠性。由於不同生物標記應用和治療領域的合格要求各不相同，監管方面的不確定性持續影響著生物標記的應用。不斷變化的監管環境給希望將生物標記整合到其開發項目中的開發人員帶來了挑戰。數據整合和解讀的挑戰進一步增加了多參數生物標記分析的複雜性。

對技術和生物標記類型的深入了解

技術發展趨勢的特徵是整合分析平台和多組體學方法的重要性日益凸顯。製藥公司需要準確評估治療過程中的生物反應，這導致對免疫檢測、定序技術和流式細胞技術的需求不斷成長。這些需求促使人們越來越依賴能夠在整個臨床試驗中產生可重複資料的先進分析系統。質譜分析正被擴大應用於全面的蛋白質體學和代謝體學學分析。分段分析表明，隨著標靶治療中對通路活性和治療反應的直接評估變得越來越必要，對蛋白質和基因生物標記的需求正在轉向蛋白質和基因生物標記。代謝體學物標記物能夠深入了解治療引起的代謝變化。細胞生物標記能夠評估免疫和細胞反應。轉錄組學生物標記能夠表徵與治療相關的基因表現變化。腫瘤學是最大的治療領域，因為標靶治療和免疫療法需要對生物活性和反應進行客觀測量。免疫學和自體免疫疾病、神經病學、心血管疾病、感染疾病和代謝性疾病是重要且快速成長的應用領域。監測藥物反應和患者分層是生物標記的主要應用領域。製藥公司是主要的終端用戶群體，生物技術公司和合約研究組織（CRO）也在不斷擴大生物標記的應用範圍。隨著生物標記開發產生龐大且多維度的資料集，人工智慧的整合變得日益重要。各機構正在採用機器學習技術來提高生物標記的識別和預測能力。

競爭格局與策略展望

競爭格局包括成熟的生命科學和診斷公司，以及專業的生物標記公司、合約研究組織 (CRO) 和轉化研究服務提供者。賽默飛世爾科技 (Thermo Fisher Scientific) 透過將分析儀器、分子生物學技術、蛋白質體學平台和臨床研究解決方案整合到一個生態系統中，並不斷加大對多組體學技術、質譜、定序解決方案和轉化研究基礎設施的投資，以滿足日益成長的生物標記需求，從而保持了獨特的戰略地位。羅氏 (Roche) 透過整合藥物開發和先進的診斷能力，並在腫瘤學、動態和神經病學領域拓展其精準醫療項目和生物標記主導的研發舉措，佔據了主導地位。丹納赫 (Danaher) 的生命科學業務支持藥效學生物標記開發的多個階段，並不斷擴展其分析技術和實驗室解決方案以改進生物標記發現和轉化研究成果，從而保持了競爭力。凱傑 (QIAGEN) 憑藉其在分子診斷和支持動態醫療計劃的專業生物標記技術方面的專長而脫穎而出，增強了其分子分析能力，並將生物標記的應用擴展到整個藥物開發項目中。安捷倫佔據著重要的市場地位，因為藥效學生物標記的開發越來越依賴能夠表徵生物反應的先進分析技術，而該公司正在擴展其分析解決方案，以改進生物標記的發現、檢驗和實用化。 Bio-Rad 仍然至關重要，因為在生物標記主導的治療開發中，定量分子分析和精確的生物學測量日益重要，這擴展了分子診斷和生命科學研究的能力。 Revvity 佔據戰略地位，因為轉化研究和體學開發對先進檢測技術和生物分析工具的需求不斷成長。 Illumina 保持強大的市場影響力，因為定序技術在生物標記的發現和分子表徵中發揮關鍵作用。每家公司都在透過在多組學平台、液態生物檢體檢測和人工智慧驅動的藥物發現工具方面的創新來擴展產品系列。在生物標記發現和檢驗需求的驅動下，診斷設備製造商、製藥公司和合約研究組織 (CRO) 之間的策略合作夥伴關係正在增加。地理擴張仍然是關鍵的策略重點，各公司將目標瞄準快速成長的亞太地區和新興市場，這些地區的藥物研發活動正在加速發展。

簡明結論

受精準醫療融合、標靶治療拓展和技術創新等因素的推動，動態標記市場預計將持續成長。從單純的研究輔助工具到治療開發的基礎要素，藥效學生物標記正經歷藥物研發領域的根本性變化。儘管生物標誌檢驗、標準化和監管不確定性等挑戰仍然存在，但對技術、夥伴關係和證據產生的策略性投資正為市場領導帶來持續的競爭優勢。長期市場前景依然樂觀，動態物標記正發展成為現代藥物研發的關鍵要素，在全球製藥和醫療保健系統中支持劑量最佳化、患者分層、治療監測和監管決策。

本報告的主要益處：

深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
實用建議：我們支援制定策略決策，以開發新的收入來源。
適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
競爭對手定位、策略和市場佔有率分析
營收成長率及預測分析：依業務板塊及地區（國家）分類
企業概況（策略、產品、財務資訊、關鍵趨勢等）

市場定義和範圍
行業概覽
產業變化
主要市場趨勢
實際成果值市場規模分析
市場預測分析
動態物標記在藥物發現中的作用
在臨床開發的各個階段活用狀況生物標記
生物標記合格評估和檢驗的現狀
患者分層分析和治療反應監測
精準醫療綜合分析
利用生物標記最佳化臨床試驗

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態
相關人員生態系統分析
合約分析和生物標記服務供應商的市場趨勢

第6章：創新趨勢

動態物標誌物的新興技術
產品創新趨勢
臨床試驗分析
動態物標誌物的管道分析
多組體學物標誌物的發展趨勢
人工智慧驅動的生物標記發現與分析
基於液態生物檢體的動態學生物標記創新
數位生物標記整合趨勢
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求
生物標記合格評估計劃
臨床檢驗與法規核准框架

第8章動態物標記市場：展望分析

分析：依生物標記類型
分析：按技術平台
分析：按治療領域
分析：按臨床開發階段
分析：依樣本類型
分析：按最終用戶
分析：透過應用
分析：按發展階段

第9章動態物標記市場：細分市場分析

依生物標誌類型
- 蛋白質生物標記
- 基因生物標記
- 代謝體學物標誌物
- 細胞生物標記
- 轉錄組生物標記
按治療區域
- 瘤
- 免疫學/自體免疫疾病
- 神經病學
- 心血管疾病
- 感染疾病
- 代謝性疾病
透過技術平台
- 免疫測量
- 次世代定序（NGS）
- 聚合酵素鏈鎖反應（PCR）
- 流式細胞技術
- 質譜分析
透過使用
- 監測藥物反應
- 劑量最佳化
- 患者分層
- 臨床試驗終點評估
- 目標參與度評估
最終用戶
- 製藥公司
- 生技公司
- CRO（委外研發機構）
- 學術研究機構
- 診斷檢查室

第10章動態物標記市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章動態物標誌物市場：國家分析

美國
加拿大
德國
英國
法國
瑞士
日本
中國
韓國
澳洲
印度
新加坡

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布
競爭基準
生物標記開發夥伴關係分析

第13章：公司簡介

Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd
Danaher Corporation
QIAGEN NV
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Revvity, Inc.
Illumina, Inc.
Charles River Laboratories International, Inc.
Labcorp Holdings Inc.
ICON plc
Syneos Health, Inc.
NeoGenomics, Inc.
Guardant Health, Inc.
SOPHiA GENETICS SA

第14章動態物標記市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資
精準醫療領域的投資趨勢
臨床生物標記研究的資金籌措趨勢
轉化醫學投資分析

第16章：未來展望

主要成長機遇
未來產業趨勢
利用生物標記進行藥物發現的演變
利用人工智慧發現動態學生物標記的前景
精準醫療和治療反應監測的未來
長期市場展望（2035 年）

簡介目錄

Product Code: KSI-009080

The Pharmacodynamic Biomarkers Market is anticipated to grow at a CAGR of 11.2% from USD 5.63 billion in 2026 to USD 14.63 billion in 2035.

The pharmacodynamic biomarkers market is undergoing significant transformation driven by the paradigm shift toward precision medicine and the growing complexity of therapeutic development. The market's evolution is characterized by the increasing recognition that objective biological indicators of treatment response are essential for demonstrating therapeutic activity, optimizing dose selection, and supporting regulatory decision-making. The convergence of advanced analytical platforms, including immunoassays, next-generation sequencing, and mass spectrometry, is enabling more precise and comprehensive measurement of biological responses to therapeutic intervention. Pharmaceutical companies are integrating pharmacodynamic biomarkers throughout clinical development because early biological evidence improves decision-making efficiency and reduces development risk. Regulatory agencies increasingly recognize biomarkers as essential tools supporting therapeutic development and precision medicine initiatives. The market is witnessing significant investment in multi-omics technologies, AI-enabled biomarker discovery, and translational research infrastructure, positioning pharmacodynamic biomarkers as a critical component of modern drug development across global healthcare and pharmaceutical ecosystems.

Market Drivers

The expansion of precision medicine initiatives represents the primary driver for the pharmacodynamic biomarkers market. Precision medicine relies on biological information capable of guiding individualized therapeutic strategies. Demand for pharmacodynamic biomarkers is increasing because treatment effectiveness increasingly depends on understanding biological responses at the patient level. This requirement creates pressure on developers to generate objective evidence supporting treatment optimization. Pharmaceutical companies are expanding biomarker programs to improve patient selection and therapeutic outcomes. The outcome is stronger integration of biomarkers across clinical development and personalized healthcare, resulting in sustained growth in pharmacodynamic biomarker utilization. The increasing adoption of targeted therapies is further accelerating market growth through demand for objective evaluation of biological activity. Targeted therapies require confirmation that therapeutic interventions affect intended biological pathways. Demand for pharmacodynamic biomarkers is rising because developers seek objective methods for evaluating target engagement and biological activity. This dependency limits reliance on traditional efficacy assessments alone. Industry participants are strengthening biomarker development efforts to improve treatment evaluation and reduce development uncertainty. The result is broader adoption of biomarker-supported therapeutic development strategies. Growing utilization in clinical trials is driving expansion of biomarker integration across therapeutic development. Clinical trials increasingly require biological evidence capable of supporting treatment evaluation and patient stratification. Demand for pharmacodynamic biomarkers is increasing because sponsors seek more efficient approaches for measuring therapeutic effects. This challenge creates pressure on researchers to develop biomarkers that accurately reflect biological responses. Organizations are integrating biomarkers into study designs to improve decision-making and resource allocation. Advancements in multi-omics technologies are accelerating innovation across pharmacodynamic biomarker development programs. Modern biomarker discovery depends on technologies capable of evaluating complex biological systems. Demand for advanced analytical platforms is rising because therapeutic development increasingly requires comprehensive characterization of molecular responses.

Market Restraints

Biomarker validation remains complex because biological responses vary across patient populations and disease states. The biological variability of treatment responses creates challenges for consistent biomarker interpretation. Standardization challenges persist because analytical methodologies and testing platforms differ across laboratories and clinical development programs. The lack of harmonized protocols reduces comparability and clinical confidence. Regulatory uncertainty continues affecting adoption because qualification requirements vary across biomarker applications and therapeutic areas. The evolving regulatory landscape creates challenges for developers seeking to integrate biomarkers into development programs. Data integration and interpretation challenges create additional complexity for multi-parameter biomarker analysis.

Technology and Biomarker Type Insights

The technology landscape is characterized by the growing importance of integrated analytical platforms and multi-omics approaches. Demand for immunoassays, sequencing technologies, and flow cytometry is increasing because drug developers require precise evaluation of biological responses during treatment. This expectation increases reliance on advanced analytical systems capable of generating reproducible data across clinical studies. Mass spectrometry is gaining adoption for comprehensive proteomic and metabolomic profiling. The segment analysis reveals that demand is shifting toward protein and genetic biomarkers because targeted therapies increasingly require direct assessment of pathway activity and treatment response. Metabolomic biomarkers provide insight into treatment-induced metabolic changes. Cellular biomarkers enable assessment of immune and cellular responses. Transcriptomic biomarkers characterize gene expression changes associated with treatment. Oncology represents the largest therapeutic area because targeted therapies and immunotherapies require objective measures of biological activity and response. Immunology and autoimmune disorders, neurology, cardiovascular diseases, infectious diseases, and metabolic disorders represent significant and growing application areas. Drug response monitoring and patient stratification represent key applications. Pharmaceutical companies represent the leading end-user segment, with biotechnology companies and CROs expanding biomarker utilization. The integration of AI is becoming increasingly important because biomarker development generates large and multidimensional datasets. Organizations are incorporating machine learning technologies to improve biomarker identification and predictive performance.

Competitive and Strategic Outlook

The competitive landscape features established life science and diagnostics companies alongside specialized biomarker, CRO, and translational research providers. Thermo Fisher Scientific maintains a strategically distinct position because the company combines analytical instrumentation, molecular biology technologies, proteomics platforms, and clinical research solutions within a single ecosystem, expanding investments in multi-omics technologies, mass spectrometry, sequencing solutions, and translational research infrastructure to address growing biomarker needs. Roche occupies a leading position because the company integrates pharmaceutical development with advanced diagnostics capabilities, expanding precision medicine programs and biomarker-driven development initiatives across oncology, immunology, and neurology. Danaher maintains competitive strength because its life sciences businesses support multiple stages of pharmacodynamic biomarker development, expanding analytical technologies and laboratory solutions to improve biomarker discovery and translational research outcomes. QIAGEN differentiates itself through molecular diagnostics expertise and biomarker-focused technologies that support precision medicine initiatives, strengthening molecular analysis capabilities and expanding biomarker applications across drug development programs. Agilent occupies an important position because pharmacodynamic biomarker development increasingly depends on advanced analytical technologies capable of characterizing biological responses, expanding analytical solutions that improve biomarker discovery, validation, and implementation activities. Bio-Rad maintains relevance because biomarker-driven therapeutic development increasingly requires quantitative molecular analysis and precise biological measurement, expanding molecular diagnostics and life science research capabilities. Revvity occupies a strategic position because translational research and biomarker development increasingly require advanced detection technologies and biological analysis tools. Illumina maintains strong market influence because sequencing technologies play a critical role in biomarker discovery and molecular characterization. Companies are pursuing product portfolio expansion through innovation in multi-omics platforms, liquid biopsy assays, and AI-enabled discovery tools. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and CROs are increasing, driven by the need for biomarker discovery and validation. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where pharmaceutical development activity is accelerating.

Short Conclusion

The pharmacodynamic biomarkers market is positioned for sustained growth driven by the convergence of precision medicine, targeted therapy expansion, and technological innovation. The transition from supportive research tools into foundational components of therapeutic development represents a fundamental shift in drug development. While challenges related to biomarker validation, standardization, and regulatory uncertainty persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with pharmacodynamic biomarkers evolving into a critical component of modern drug development, supporting dose optimization, patient stratification, treatment monitoring, and regulatory decision-making across global pharmaceutical and healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Pharmacodynamic Biomarkers Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast Analysis (2026-2035)
3.7 Role of Pharmacodynamic Biomarkers in Drug Development
3.8 Biomarker Utilization Across Clinical Development Phases
3.9 Biomarker Qualification and Validation Landscape
3.10 Patient Stratification and Response Monitoring Analysis
3.11 Precision Medicine Integration Analysis
3.12 Biomarker-Driven Clinical Trial Optimization

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape
5.4 Stakeholder Ecosystem Analysis
5.5 Contract Research and Biomarker Service Provider Landscape

6. Innovation Landscape

6.1 Emerging Technologies in Pharmacodynamic Biomarkers
6.2 Product Innovation Trends
6.3 Clinical Trial Analysis
6.4 Pharmacodynamic Biomarker Pipeline Analysis
6.5 Multi-omics Biomarker Development Trends
6.6 AI-Enabled Biomarker Discovery and Analysis
6.7 Liquid Biopsy-Based Pharmacodynamic Biomarker Innovation
6.8 Digital Biomarker Integration Trends
6.9 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements
7.4 Biomarker Qualification Programs
7.5 Clinical Validation and Regulatory Acceptance Frameworks

8. Pharmacodynamic Biomarkers Market Landscape Analysis

8.1 Analysis by Biomarker Type
8.2 Analysis by Technology Platform
8.3 Analysis by Therapeutic Area
8.4 Analysis by Clinical Development Phase
8.5 Analysis by Sample Type
8.6 Analysis by End User
8.7 Analysis by Application
8.8 Analysis by Development Stage

9. Pharmacodynamic Biomarkers Market Segment Analysis (2021-2035)

9.1 By Biomarker Type
- 9.1.1 Protein Biomarkers
- 9.1.2 Genetic Biomarkers
- 9.1.3 Metabolomic Biomarkers
- 9.1.4 Cellular Biomarkers
- 9.1.5 Transcriptomic Biomarkers
9.2 By Therapeutic Area
- 9.2.1 Oncology
- 9.2.2 Immunology and Autoimmune Disorders
- 9.2.3 Neurology
- 9.2.4 Cardiovascular Diseases
- 9.2.5 Infectious Diseases
- 9.2.6 Metabolic Disorders
9.3 By Technology Platform
- 9.3.1 Immunoassays
- 9.3.2 Next-Generation Sequencing (NGS)
- 9.3.3 Polymerase Chain Reaction (PCR)
- 9.3.4 Flow Cytometry
- 9.3.5 Mass Spectrometry
9.4 By Application
- 9.4.1 Drug Response Monitoring
- 9.4.2 Dose Optimization
- 9.4.3 Patient Stratification
- 9.4.4 Clinical Trial Endpoint Assessment
- 9.4.5 Target Engagement Assessment
9.5 By End User
- 9.5.1 Pharmaceutical Companies
- 9.5.2 Biotechnology Companies
- 9.5.3 Contract Research Organizations (CROs)
- 9.5.4 Academic and Research Institutes
- 9.5.5 Diagnostic Laboratories